<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00607178</url>
  </required_header>
  <id_info>
    <org_study_id>SBMU- 86-03-105-5433A</org_study_id>
    <secondary_id>SMMC- 13861008A</secondary_id>
    <nct_id>NCT00607178</nct_id>
  </id_info>
  <brief_title>The Efficacy of Influenza Vaccine in Reducing Cardiovascular Events in Patients With Coronary Artery Diseases</brief_title>
  <acronym>IVCAD</acronym>
  <official_title>Randomized, Single-Blind, Placebo-Controlled Study of Influenza Vaccine in Preventing Cardiovascular Events in Post-Myocardial Infarction Patients and in Those With Stable Angina Pectoris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Influenza vaccine reduces the cardiovascular events in post-myocardial infarction (MI)
      patients and in those with stable angina (SA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A connection between infectious processes and atherosclerosis is repeatedly reported [1].
      Acute respiratory infection was found to be associated with myocardial infarction (MI) [2,3]
      and a number of epidemiological studies found that mortality attributable to cardiovascular
      diseases is increased during influenza epidemics [4]. Naghavi et al [5] in a case-control
      study of patients with coronary artery disease (CAD) found that vaccination against influenza
      was negatively associated with the development of new MI during the same influenza season.
      While some clinical trials found influenza vaccine effective in secondary prevention of
      cardiovascular adverse events [6,7], a large trial [8] failed to approve such an efficacy.
      Furthermore, a recent review of published trials on the subject concluded that frailty
      selection bias and use of non-specific endpoints such as all cause mortality have led cohort
      studies to greatly exaggerate vaccine benefits and that the remaining evidence base is
      currently insufficient to indicate the magnitude of the mortality benefit of the vaccination
      program [9].

      This study aims to assess the efficacy of vaccine in secondary prevention of cardiovascular
      events in MI and stable angina (SA) patients using specific endpoints including reliable
      quantitative tools.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiovascular death</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute coronary syndrome (MI or unstable angina)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Admission for Coronary Artery Disease</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angina severity (Seattle Angina Questionnaire [10])</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary artery stenosis (modified Gensini score [11])</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary revascularization (artery bypass graft or percutaneous coronary intervention)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influenza infection</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Coronary Artery Diseases</condition>
  <condition>Myocardial Infarction</condition>
  <condition>Stable Angina</condition>
  <arm_group>
    <arm_group_label>Influenza vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrolled patients who are randomly assigned to receive influenza vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Enrolled patients who are randomly assigned to receive placebo of influenza vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>influenza vaccine</intervention_name>
    <description>Intramuscular injection of one 0.5-mL dose of influenza vaccine</description>
    <arm_group_label>Influenza vaccine</arm_group_label>
    <other_name>2006-2007 vaccination campaign of Influvac (SolvayPharma)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>placebo for influenza vaccine</intervention_name>
    <description>Intramuscular injection of one 0.5-mL dose of placebo for influenza vaccine</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with the diagnosis of acute, evolving or recent MI (after recovered the acute
             phase) as defined by:

               1. Typical rise and gradual fall (troponin) or more rapid rise and fall (CK-MB) of
                  biochemical markers of myocardial necrosis with at least one of the following:

                    -  Ischemic symptoms

                    -  Development of pathologic Qwaves on the ECG

                    -  ECG changes indicative of ischemia (ST segment elevation or depression); OR

                    -  Coronary artery intervention (e.g., coronary angioplasty).

               2. Pathologic findings of an acute MI [12]

          -  Patients with stable angina pectoris and documented coronary artery stenosis
             (angiography).

        Exclusion Criteria:

          -  Any acute disease

          -  Chronic liver or kidney diseases

          -  Conditions accompanied by immunosuppression (like organ transplantation, HIV)

          -  Diagnosed malignancy

          -  Incubation with influenza vaccine within the past 5 years

          -  Any psychological disease that interferes with regular follow-up

          -  Congestive heart failure (Killip class IV)

          -  Unstable angina, and contradictions of vaccine incubation (like egg allergy).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maryam Keshtkar-Jahromi, M.D.; M.P.H.</last_name>
    <role>Study Chair</role>
    <affiliation>Infectious Diseases and Tropical Medicine Research Center, Shaheed Beheshti Medical University, Tehran, Iran</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hossein Vakili, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiovascular Research Center, Shaheed Beheshti Medical University, Tehran, Iran</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ali Eskandari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohammad Rahnavardi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sharareh Gholamin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shaheed Beheshti University (MC)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seyed Mostafa Razavi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shaheed Beheshti University (MC)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shaheed Modarres Medical Center</name>
      <address>
        <city>Tehran</city>
        <zip>19814</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <reference>
    <citation>Gurfinkel E, Lernoud V. The role of infection and immunity in atherosclerosis. Expert Rev Cardiovasc Ther. 2006 Jan;4(1):131-7. Review.</citation>
    <PMID>16375635</PMID>
  </reference>
  <reference>
    <citation>Spodick DH, Flessas AP, Johnson MM. Association of acute respiratory symptoms with onset of acute myocardial infarction: prospective investigation of 150 consecutive patients and matched control patients. Am J Cardiol. 1984 Feb 1;53(4):481-2.</citation>
    <PMID>6695777</PMID>
  </reference>
  <reference>
    <citation>Bainton D, Jones GR, Hole D. Influenza and ischaemic heart disease--a possible trigger for acute myocardial infarction? Int J Epidemiol. 1978 Sep;7(3):231-9.</citation>
    <PMID>721358</PMID>
  </reference>
  <reference>
    <citation>Gurevich VS. Influenza, autoimmunity and atherogenesis. Autoimmun Rev. 2005 Feb;4(2):101-5. Epub 2004 Nov 20. Review.</citation>
    <PMID>15722256</PMID>
  </reference>
  <reference>
    <citation>Naghavi M, Barlas Z, Siadaty S, Naguib S, Madjid M, Casscells W. Association of influenza vaccination and reduced risk of recurrent myocardial infarction. Circulation. 2000 Dec 19;102(25):3039-45.</citation>
    <PMID>11120692</PMID>
  </reference>
  <reference>
    <citation>Gurfinkel EP, de la Fuente RL, Mendiz O, Mautner B. Influenza vaccine pilot study in acute coronary syndromes and planned percutaneous coronary interventions: the FLU Vaccination Acute Coronary Syndromes (FLUVACS) Study. Circulation. 2002 May 7;105(18):2143-7.</citation>
    <PMID>11994246</PMID>
  </reference>
  <reference>
    <citation>Le√≥n de la Fuente R, Gurfinkel EP, Toledo D, Mautner B; Grupo de Estudio FLUVACS. [Flu vaccination in patients with acute coronary syndromes: treatment benefit in prespecified subgroups]. Rev Esp Cardiol. 2003 Oct;56(10):949-54. Spanish.</citation>
    <PMID>14563288</PMID>
  </reference>
  <reference>
    <citation>Jackson LA, Yu O, Heckbert SR, Psaty BM, Malais D, Barlow WE, Thompson WW; Vaccine Safety Datalink Study Group. Influenza vaccination is not associated with a reduction in the risk of recurrent coronary events. Am J Epidemiol. 2002 Oct 1;156(7):634-40.</citation>
    <PMID>12244032</PMID>
  </reference>
  <reference>
    <citation>Simonsen L, Taylor RJ, Viboud C, Miller MA, Jackson LA. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis. 2007 Oct;7(10):658-66. Review.</citation>
    <PMID>17897608</PMID>
  </reference>
  <reference>
    <citation>Spertus JA, Winder JA, Dewhurst TA, Deyo RA, Prodzinski J, McDonell M, Fihn SD. Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease. J Am Coll Cardiol. 1995 Feb;25(2):333-41.</citation>
    <PMID>7829785</PMID>
  </reference>
  <reference>
    <citation>Gensini GG. Coronary Angiography. Mount Kisco, NY: Futura Publishing Co; 1975.</citation>
  </reference>
  <reference>
    <citation>Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000 Sep;36(3):959-69. Erratum in: J Am Coll Cardiol 2001 Mar 1;37(3):973.</citation>
    <PMID>10987628</PMID>
  </reference>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2008</study_first_submitted>
  <study_first_submitted_qc>February 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2008</study_first_posted>
  <last_update_submitted>January 20, 2009</last_update_submitted>
  <last_update_submitted_qc>January 20, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2009</last_update_posted>
  <responsible_party>
    <name_title>Maryam Keshtkar-Jahromi</name_title>
    <organization>Infectious Diseases and Tropical Medicine Research Center, SBMU, Tehran, Iran</organization>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

